Abatacept with FluBu2: To Use or Not to Use
In 2021, the FDA approved using abatacept (ABA) for acute graft versus host disease (aGVHD) prevention in adults and pediatric patients 2 years of age and older undergoing hematopoietic stem cell transplantation (SCT) from a matched (MUD) or 1 allele-mismatched unrelated donor (MMUD), based on the phase II ABA2 study. In that study, there was no difference in engraftment or relapse between patients who received ABA and those who did not. However, this study included a significant number of young patients (median age
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Luis F Gonzalez-Mosquera, Mrs. Klodiana Neme, Nancy Mikulandric, Izabela Mazur, Josephine Emole, Asif Alavi, Edward Peres, Muneer H. Abidi, Shatha Farhan Tags: 206 Source Type: research
More News: Abatacept | Biology | Hematology | Orencia | Pediatrics | Stem Cell Therapy | Stem Cells | Study | Transplants